Emerging evidence indicates epigenetic modification represses
estrogen receptor α (ERα) and contributes to the resistance to
tamoxifen in aggressive ERα-negative (ERα-)
breast cancer.
Z-ligustilide is a major compound in Radix Angelica sinensis, an herb from
traditional Chinese medicine (TCM) most frequently prescribed for
breast cancer. However, the role of
Z-ligustilide in ERα-
breast cancer and epigenetic modification remains largely unknown. Herein we showed, for the first time, that
Z-ligustilide restored the growth inhibition of
tamoxifen on ERα-
breast cancer cells. Apoptosis and S and G2/M phases cell cycle arrest were induced by combinatorial
Z-ligustilide and
tamoxifen. Importantly,
Z-ligustilide reactivated the ERα expression and transcriptional activity, which is proved to be indispensable for restoring the sensitivity to
tamoxifen. Interestingly,
Z-ligustilide increased Ace-H3 (lys9/14) enrichment in the ERα promoter. Moreover,
Z-ligustilide dramatically reduced the enrichment of
metastasis-associated
protein 1 (MTA1) as well as IFN-γ-inducible
protein 16 (IFI16) and
histone deacetylases (HDACs) onto the ERα promoter. Meanwhile,
Z-ligustilide downregulated MTA1, IFI16 and HDACs, which caused destabilization of the
corepressor complex. Collectively, our study not only highlights
Z-ligustilide as a novel epigenetic modulator, but also opens new possibilities from TCM for treating aggressive
tamoxifen-resistant
breast cancer.